ATE485375T1 - Nukleinsäuren zum auslösen der tumorzellsterblichkeit - Google Patents
Nukleinsäuren zum auslösen der tumorzellsterblichkeitInfo
- Publication number
- ATE485375T1 ATE485375T1 AT04817274T AT04817274T ATE485375T1 AT E485375 T1 ATE485375 T1 AT E485375T1 AT 04817274 T AT04817274 T AT 04817274T AT 04817274 T AT04817274 T AT 04817274T AT E485375 T1 ATE485375 T1 AT E485375T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleic acids
- tumor cell
- cell mortality
- trigger tumor
- trigger
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 title 1
- 230000001173 tumoral effect Effects 0.000 abstract 2
- 230000033616 DNA repair Effects 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003855 cell nucleus Anatomy 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 231100000225 lethality Toxicity 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03292666A EP1526177A1 (en) | 2003-10-24 | 2003-10-24 | Nucleic acids useful for triggering tumor cell lethality |
| PCT/EP2004/012857 WO2005040378A1 (en) | 2003-10-24 | 2004-10-25 | Nucleic acids useful for triggering tumor cell lethality |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE485375T1 true ATE485375T1 (de) | 2010-11-15 |
Family
ID=34384721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04817274T ATE485375T1 (de) | 2003-10-24 | 2004-10-25 | Nukleinsäuren zum auslösen der tumorzellsterblichkeit |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7595302B2 (https=) |
| EP (2) | EP1526177A1 (https=) |
| JP (2) | JP4743789B2 (https=) |
| CN (1) | CN1871350B (https=) |
| AT (1) | ATE485375T1 (https=) |
| AU (1) | AU2004284228B2 (https=) |
| CA (1) | CA2542942C (https=) |
| CY (1) | CY1111060T1 (https=) |
| DE (1) | DE602004029699D1 (https=) |
| DK (1) | DK1675954T3 (https=) |
| ES (1) | ES2354359T3 (https=) |
| PL (1) | PL1675954T3 (https=) |
| PT (1) | PT1675954E (https=) |
| SI (1) | SI1675954T1 (https=) |
| WO (1) | WO2005040378A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7476729B2 (en) * | 2003-10-24 | 2009-01-13 | Institut Curie | Dbait and uses thereof |
| EP1944369A1 (en) * | 2007-01-12 | 2008-07-16 | The Centre National de la Recherche Scientifique | Dbait and its standalone uses thereof |
| WO2009149921A2 (en) * | 2008-06-11 | 2009-12-17 | Bionucleon S.R.L. | Inhibition of hrp-3 using modified oligonucleotides |
| US9205099B2 (en) | 2010-06-22 | 2015-12-08 | Dna Therapeutics | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
| AU2015202211B2 (en) * | 2010-06-22 | 2016-09-01 | Centre National De La Recherche Scientifique | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
| EP2527440A1 (en) * | 2011-05-27 | 2012-11-28 | Institut Curie | Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia |
| AU2014316676B2 (en) * | 2013-09-04 | 2020-07-23 | Csir | Site-specific nuclease single-cell assay targeting gene regulatory elements to silence gene expression |
| EP3919621A1 (en) * | 2014-06-23 | 2021-12-08 | The General Hospital Corporation | Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq) |
| JP6457696B2 (ja) | 2015-07-23 | 2019-01-23 | アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ | 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用 |
| US10821128B2 (en) * | 2016-03-01 | 2020-11-03 | Onxeo | Treatment of cancer by systemic administration of Dbait molecules |
| WO2017186882A1 (en) | 2016-04-29 | 2017-11-02 | Onxeo | A method of predicting a response to an anti-tumor treatment by means of signal interfering dna molecules |
| US10876116B2 (en) | 2016-07-15 | 2020-12-29 | The Board Of Regents Of The University Of Oklahoma | Anti-ARID3a treatments for inflammatory disorders |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| EP3461488A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
| CN108261548B (zh) * | 2018-01-10 | 2020-04-10 | 浙江大学 | 一种纳米复合物及其制备方法和应用 |
| KR20200130856A (ko) | 2018-03-13 | 2020-11-20 | 옹쎄오 | 암 치료에서 획득한 내성에 대한 디베이트 분자 |
| CA3097044A1 (en) | 2018-04-17 | 2019-10-24 | The General Hospital Corporation | Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents |
| WO2020127965A1 (en) | 2018-12-21 | 2020-06-25 | Onxeo | New conjugated nucleic acid molecules and their uses |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202210633A (zh) | 2020-06-05 | 2022-03-16 | 法商昂席歐公司 | 用於治療癌症之dbait分子與kras抑制劑的組合 |
| AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
| JP2025500922A (ja) | 2021-12-16 | 2025-01-15 | ヴァレリオ・セラピューティクス | 新規のコンジュゲートされた核酸分子及びその使用 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ255028A (en) * | 1992-07-02 | 1997-03-24 | Hybridon Inc | Antisense oligonucleotides resistant to nucleolytic degradation |
| US6441158B1 (en) * | 1997-12-31 | 2002-08-27 | Medical College Of Georgia Research Institute, Inc. | Oligomers that bind to ku protein |
| EP0978561A1 (en) * | 1998-08-07 | 2000-02-09 | Hoechst Marion Roussel Deutschland GmbH | Antisense oligonucleotides for the inhibition of VEGF expression |
| AU2002241952A1 (en) * | 2001-01-22 | 2002-07-30 | Genta Incorporated | Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers |
| CA2476468A1 (en) | 2002-02-13 | 2003-08-21 | Medbridge, Inc. | Protein carrier system for therapeutic oligonucleotides |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
-
2003
- 2003-10-24 EP EP03292666A patent/EP1526177A1/en not_active Withdrawn
-
2004
- 2004-10-25 CA CA2542942A patent/CA2542942C/en not_active Expired - Lifetime
- 2004-10-25 PT PT04817274T patent/PT1675954E/pt unknown
- 2004-10-25 ES ES04817274T patent/ES2354359T3/es not_active Expired - Lifetime
- 2004-10-25 DK DK04817274.6T patent/DK1675954T3/da active
- 2004-10-25 AU AU2004284228A patent/AU2004284228B2/en not_active Expired
- 2004-10-25 US US10/576,818 patent/US7595302B2/en not_active Expired - Lifetime
- 2004-10-25 PL PL04817274T patent/PL1675954T3/pl unknown
- 2004-10-25 CN CN200480031278.XA patent/CN1871350B/zh not_active Expired - Lifetime
- 2004-10-25 WO PCT/EP2004/012857 patent/WO2005040378A1/en not_active Ceased
- 2004-10-25 AT AT04817274T patent/ATE485375T1/de active
- 2004-10-25 DE DE602004029699T patent/DE602004029699D1/de not_active Expired - Lifetime
- 2004-10-25 EP EP04817274A patent/EP1675954B1/en not_active Expired - Lifetime
- 2004-10-25 JP JP2006536073A patent/JP4743789B2/ja not_active Expired - Lifetime
- 2004-10-25 SI SI200431547T patent/SI1675954T1/sl unknown
-
2010
- 2010-12-23 CY CY20101101190T patent/CY1111060T1/el unknown
-
2011
- 2011-02-10 JP JP2011027662A patent/JP5662822B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005040378A1 (en) | 2005-05-06 |
| CN1871350B (zh) | 2014-10-15 |
| DK1675954T3 (da) | 2011-01-10 |
| EP1675954A1 (en) | 2006-07-05 |
| CY1111060T1 (el) | 2015-06-11 |
| AU2004284228B2 (en) | 2010-04-08 |
| PL1675954T3 (pl) | 2011-04-29 |
| JP4743789B2 (ja) | 2011-08-10 |
| SI1675954T1 (sl) | 2011-01-31 |
| ES2354359T3 (es) | 2011-03-14 |
| CA2542942C (en) | 2014-04-29 |
| JP2007510405A (ja) | 2007-04-26 |
| US20070197458A1 (en) | 2007-08-23 |
| JP2011126897A (ja) | 2011-06-30 |
| PT1675954E (pt) | 2010-12-27 |
| EP1526177A1 (en) | 2005-04-27 |
| US7595302B2 (en) | 2009-09-29 |
| JP5662822B2 (ja) | 2015-02-04 |
| DE602004029699D1 (de) | 2010-12-02 |
| CN1871350A (zh) | 2006-11-29 |
| CA2542942A1 (en) | 2005-05-06 |
| AU2004284228A1 (en) | 2005-05-06 |
| EP1675954B1 (en) | 2010-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111060T1 (el) | Νουκλεϊκα οξεα χρησιμα για την πυροδοτηση της θνησιμοτητας κυτταρων ογκου | |
| PT1548032E (pt) | Péptidos kdr e vacinas que os contêm | |
| HRP20070012A2 (hr) | Imunostimulatorski oligonukleotidni multimeri | |
| EP2003196A3 (en) | Compositions and methods for treating and diagnosing cancer | |
| EP2730587A3 (en) | Genes for enhancing nitrogen utilization efficiency in crop plants | |
| ES2534303T3 (es) | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN | |
| WO2004037977A3 (en) | Use of chimeric nucleases to stimulate gene targeting | |
| AR049188A1 (es) | Adenovirus quimericos para uso en el tratamiento del cancer | |
| WO2008140621A3 (en) | Transgenic oncolytic viruses and uses thereof | |
| DE60310202D1 (de) | Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen | |
| WO2006018836A3 (en) | Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues | |
| TR200202196T2 (tr) | Homolog yeniden kombine etmeyi iyileştirme yöntemleri | |
| MY131964A (en) | 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | |
| AR054526A1 (es) | Metodo para tartar pacientes con una vacuna de glicoproteina mucinosa (muc-1) | |
| WO2005030928A3 (en) | PORCINE INVARIANT CHAIN PROTEIN, FULL LENGTH cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION | |
| AR039185A1 (es) | Celulas hospedantes que tienen propiedades mejoradas de supervivencia celular y metodos para generar estas celulas | |
| DK1664102T3 (da) | Isoleret photoprotein mtclytin, samt dets anvendelse | |
| WO2005007098A3 (en) | Nucleic acid therapy to enhance cartilage repair | |
| WO2003090778A3 (en) | Dna vaccine combined with an inducer of tumor cell apoptosis | |
| RU2003101855A (ru) | Средство, нормализующее структуру и функции органов и тканей, стимулирующее репарирование повреждений, обладающее противовирусной активностью, и способ его получения | |
| DE60310708D1 (de) | In vivo stabilsierung von plasmiden | |
| WO2004011623A3 (en) | Antisense modulation of ptpra expression | |
| WO2003106645A3 (en) | ANTISENSE MODULATION OF SMRT COREPRESSOR EXPRESSION | |
| WO2003016839A3 (en) | Modified railroad worm red luciferase coding sequences | |
| CY1114199T1 (el) | Αντιπληροφοριακη διαμορφωση της εκφρασης της απολιποπρωτεϊνης β |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1675954 Country of ref document: EP |